Jun 2026
Conyers provided Bermuda legal advice to Luye Pharma Group Ltd. (“Luye Pharma”) in connection with its offer to purchase its outstanding US$180 million 6.25% convertible bonds due 2028 and its issue of an aggregate principal amount of US$180 million 5.25% convertible bonds due 2031 convertible into ordinary shares of Luye Pharma.
Luye Pharma and its subsidiaries focus on developing, producing, marketing and selling innovative pharmaceutical products in four of the largest and fastest growing therapeutic areas in the PRC, the United States, Europe and other emerging countries or regions, namely oncology, central nervous system, cardiovascular system, alimentary tract and metabolism.
Partner Ryan McConvey of Conyers’ Hong Kong office and Counsel Rita Leung of Conyers’ Singapore office advised on the matter working alongside A&O Shearman.